Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 11INDUSTRY 10NIH 4NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Breast Neoplasms 22Prostatic Neoplasms 18Carcinoma, Non-Small-Cell Lung 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Multiple Myeloma 14Lymphoma 12Colorectal Neoplasms 12Neoplasms 9Melanoma 9Lung Neoplasms 8Leukemia, Myeloid, Acute 8Pancreatic Neoplasms 7Lymphoma, Non-Hodgkin 7Wilms Tumor 6Leukemia, Biphenotypic, Acute 6HIV Infections 6Burkitt Lymphoma 6Squamous Cell Carcinoma of Head and Neck 5Lymphoma, Mantle-Cell 5Hematologic Neoplasms 5Head and Neck Neoplasms 5Ependymoma 5Colonic Neoplasms 5Rectal Neoplasms 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 4Osteosarcoma 4Medulloblastoma 4Malignant Solid Neoplasm 4

Interventions

Temozolomide 1Etoposide 1Cisplatin 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Carcinoma, Neuroendocrine × 90 days × Clear all
NCT02595424 2026-05-01

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
67 enrolled 13 charts
Endocrine

Somatostatinoma, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡